SCHEMBL12419199

SCHEMBL12419199

COc1cc(-c2ccccc2)cn2ncc(-c3csc(C(=O)N[C@H]4CCCC[C@H]4N)c3)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 12/20 0.59
SYK P43405 3/20 0.59
IRAK4 Q9NWZ3 2/20 0.59
JAK2 O60674 2/20 0.59
JAK1 P23458 2/20 0.59
TYK2 P29597 2/20 0.59
JAK3 P52333 2/20 0.59
SGK1 O00141 1/20 0.59
PIK3CD O00329 1/20 0.59
CHEK1 O14757 1/20 0.59
MAPK13 O15264 1/20 0.59
PDPK1 O15530 1/20 0.59
NUAK1 O60285 1/20 0.59
CCNT1 O60563 1/20 0.59
ROCK2 O75116 1/20 0.59
CHEK2 O96017 1/20 0.59
ABL1 P00519 1/20 0.59
EGFR P00533 1/20 0.59
RAF1 P04049 1/20 0.59
ERBB2 P04626 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12379630 1.00 MARK3 (0.59) MARK3SYKIRAK4JAK2JAK1
SCHEMBL12379632 0.81 GAK (0.43) MARK3IRAK4JAK2JAK1TYK2
SCHEMBL2288466 0.81 GAK (0.43) MARK3SYKIRAK4JAK2JAK1
SCHEMBL12418265 0.79 MMP12 (0.48) MARK3SYKIRAK4JAK2JAK1
SCHEMBL12379636 0.78 MARK3 (0.46) MARK3MAPK13ROCK2KITPRKACA
SCHEMBL12379644 0.78 MARK3 (0.61) MARK3SYKIRAK4JAK2JAK1
SCHEMBL2291469 0.75 MARK3 (0.59) MARK3SYKIRAK4JAK2JAK1
SCHEMBL3761756 0.74 MARK3 (1.00) MARK3SYKIRAK4JAK2JAK1
SCHEMBL3761722 0.74 MARK3 (1.00) MARK3SYKIRAK4JAK2JAK1
SCHEMBL3769201 0.74 MARK3 (1.00) MARK3SYKIRAK4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
EP-2320737-B1 PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed
WO-2010017046-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MARK3, MARK4, MARK1 MARK3 1/4885SYK 1948/4885IRAK4 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.